Author

Omar I. Vivar

Observed names: O. Vivar, O.I. Vivar, Omar I Vivar, Omar Vivar, Omar I. Vivar, Vivar, Omar I.

Observed institutions: Inserm, University of California, San Francisco, Université Paris Sciences et Lettres, Nanobiotix (France), Immunité et Cancer, Institut Curie, University of California, Berkeley

ORCID: 0009-0000-1461-3690

Observed ORCID: 0009-0000-1461-3690

OpenAlex ID: A5031303187

Toll-like Receptor 4 Engagement on Dendritic Cells Restrains Phago-Lysosome Fusion and Promotes Cross-Presentation of Antigens

2015 · Andrés Alloatti, Fiorella Kotsias, et al. · Immunity · 202

PDF

Regulation of specific target genes and biological responses by estrogen receptor subtype agonists

2010 · Dale C Leitman, Sreenivasan Paruthiyil, et al. · Current Opinion in Pharmacology · 110

Estrogen Receptor β Binds to and Regulates Three Distinct Classes of Target Genes

2010 · Omar I. Vivar, Xiaoyue Zhao, et al. · Journal of Biological Chemistry · 106

IFT20 controls LAT recruitment to the immune synapse and T-cell activation in vivo

2015 · Omar I. Vivar, Giulia Masi, et al. · Proceedings of the National Academy of Sciences · 69

3,3′-Diindolylmethane induces a G1 arrest in human prostate cancer cells irrespective of androgen receptor and p53 status

2009 · Omar I. Vivar, Chia-Lei Lin, et al. · Biochemical Pharmacology · 61

Selective Activation of Estrogen Receptor-β Target Genes by 3,3′-Diindolylmethane

2010 · Omar I. Vivar, Elise F. Saunier, et al. · Endocrinology · 37

PDF

International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers

2024 · Xavier Liem, Thierry de Baère, et al. · Head & Neck · 23

PDF

Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC

2025 · Christophe Le Tourneau, Zoltán Takácsi-Nagy, et al. · Future Oncology · 22

PDF

Unliganded estrogen receptor-β regulation of genes is inhibited by tamoxifen

2009 · Nitzan Levy, Sreenivasan Paruthiyil, et al. · Molecular and Cellular Endocrinology · 22

Intratumoral Radioenhancer Nanoparticle NBTXR3 Followed by Radiotherapy in Head and Neck Cancer: A Phase 1 Dose-Expansion Nonrandomized Clinical Trial

2026 · Christophe Le Tourneau, Xavier Liem, et al. · JAMA Otolaryngology–Head & Neck Surgery · 13

The radioenhancer NBTXR3: bridging physics and biology to improve radiotherapy outcomes and prime anti-tumor immunity

2025 · Célia Bienassis, Omar I. Vivar, et al. · Journal of Experimental & Clinical Cancer Research · 13

PDF

Imaging Features of Intratumoral Injection of NBTXR3 for Head and Neck Squamous Cell Carcinoma Lymph Node Metastases

2022 · Daniel Thomas Ginat, Aditya Juloori, et al. · Diagnostics · 13

PDF

Estrogenic Plant Extracts Reverse Weight Gain and Fat Accumulation without Causing Mammary Gland or Uterine Proliferation

2011 · Elise F. Saunier, Omar I. Vivar, et al. · PLoS ONE · 13

PDF

Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.

2023 · Colette Shen, Jessica M. Frakes, et al. · Journal of Clinical Oncology · 9

NANORAY-312: A Phase III Pivotal Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-Based Chemotherapy-Ineligible Elderly Patients with Locally Advanced HNSCC

2022 · S.S. Yom, Z. Takacsi-Nagy, et al. · International Journal of Radiation Oncology*Biology*Physics · 8

Radioenhancing Hafnium Oxide Nanoparticles (NBTXR3) Followed by Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma and Liver Metastases (NBTXR3-103): Phase 1 Dose-Escalation Trial

2025 · Enrique Chajon, Marc Pracht, et al. · Advances in Radiation Oncology · 7

PDF

684 NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers: results from an ongoing dose escalation phase I trial (Study 1100)

2022 · Colette Shen, Jessica Frakes, et al. · Journal for ImmunoTherapy of Cancer · 7

PDF

Measurement of Export to the Cytosol in Dendritic Cells Using a Cytofluorimetry-Based Assay

2016 · Omar I. Vivar, Joao G. Magalhaes, et al. · Methods in molecular biology · 7

Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100.

2024 · Colette Shen, Jessica M. Frakes, et al. · Journal of Clinical Oncology · 5

PDF

Phase I Dose Escalation/Dose Expansion Trial of NBTXR3/SBRT in Combination with Nivolumab or Pembrolizumab for the Treatment of Anti-PD-1 Naïve or Resistant Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

2025 · C. Shen, A. Sukari, et al. · International Journal of Radiation Oncology*Biology*Physics · 3

PDF

Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients: Final and Exploratory Results of a Phase I Trial

2024 · C. Le Tourneau, X. Liem, et al. · International Journal of Radiation Oncology*Biology*Physics · 3

887P Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients

2023 · C. Le Tourneau, Z. Takacsi-Nagy, et al. · Annals of Oncology · 3

PDF

1631P Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)

2023 · G. Fuentes, M.J. Rodriguez, et al. · Annals of Oncology · 2

PDF

255P: NBTXR3 activated by SBRT in combination with nivolumab or pembrolizumab for the treatment of patients with lung metastases from NSCLC or other solid tumours in the phase I trial study 1100

2025 · C. Shen, A. Juloori, et al. · Journal of Thoracic Oncology · 1

417P Final and exploratory results of a phase I trial evaluating novel radioenhancer NBTXR3 activated by radiotherapy in cisplatin-ineligible LA HNSCC patients

2024 · C. Le Tourneau, X. Liem, et al. · Annals of Oncology · 1

Works count: 39

Citation count: 764

H-index: 13

I10-index: 13